Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial (Q46649423)

23 December 2017

title

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial (English)

1 reference

23 December 2017

chronic obstructive pulmonary disease

main subject

inflammation

0 references

0 references

1

Klaus F Rabe

1 reference

23 December 2017

author name string

Eric D Bateman

2

1 reference

23 December 2017

Denis O'Donnell

3

1 reference

23 December 2017

Stephan Witte

4

1 reference

23 December 2017

Dirk Bredenbröker

5

1 reference

23 December 2017

Thomas D Bethke

6

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

published in

The Lancet

1 reference

23 December 2017

volume

366

1 reference

23 December 2017

issue

9485

1 reference

23 December 2017

page(s)

563-571

1 reference

23 December 2017

Interpreting COPD prevalence estimates: what is the true burden of disease?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Burden and clinical features of chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Epidemiology of chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Pathophysiology of airflow limitation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Chronic obstructive pulmonary disease: molecular and cellularmechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Breathlessness in patients with chronic airflow limitation. Mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967100-0

7 January 2021

10.1016/S0140-6736(05)67100-0

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017